Txl Active Wart Remover Pads

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts, which are characterized by their rough, 'cauliflower-like' surface appearance.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed, and it is recommended to soak the wart in warm water for approximately 5 minutes. After soaking, the area must be dried thoroughly to ensure proper adhesion of the medicated plaster.

To apply the medicated plaster, healthcare professionals should first remove the bandage strips by peeling the backing off. If necessary, the medicated patch may be cut to fit the size of the wart. The plaster should then be carefully applied to the wart.

This procedure may be repeated every 48 hours as needed, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated, infected, or reddened skin is not recommended due to the potential for exacerbating the condition. The product should not be used on genital warts or warts located on the face, as these areas may have different sensitivities and risks associated with treatment. Additionally, the use of this product on moles, birthmarks, or warts with hair growing from them is contraindicated to prevent adverse reactions. Application on mucous membranes is also prohibited due to the risk of irritation and other complications.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to consult a physician prior to use if they have diabetes or experience poor blood circulation, as these conditions may increase the risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Patients should be instructed to discontinue use and contact their healthcare provider if any of the following conditions are present: irritated, infected, or reddened skin; genital warts; warts located on the face; moles; birthmarks; or warts with hair growing from them. Additionally, this product should not be applied to mucous membranes, as this may lead to unwanted complications.

Side Effects

Patients should be advised that the product is for external use only. This warning is critical to ensure safe and appropriate use, minimizing the risk of adverse reactions associated with improper application.

No specific adverse reactions have been reported in clinical trials or postmarketing experiences beyond the stated warning. However, healthcare providers should remain vigilant for any unexpected reactions in patients using the product, particularly in those with sensitive skin or underlying dermatological conditions.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Txl Active Wart Remover Pads (wart remover pads). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients should be aware that the safety of this medication during pregnancy has not been explicitly established. There are no specific data regarding the potential risks or fetal impacts associated with the use of this medication in pregnant individuals. Healthcare professionals are advised to consider the lack of information on safety and efficacy when prescribing this medication to women of childbearing potential. It is recommended that the benefits and risks be carefully weighed before initiating treatment in this population. Further studies may be necessary to elucidate the implications of this medication on pregnancy outcomes.

Lactation

There is no specific information regarding the use of this drug in lactating mothers or any lactation considerations provided in the drug insert. Therefore, healthcare professionals should exercise caution when prescribing this medication to nursing mothers, as the effects on breastfed infants are not established.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or toxicology expert may also be warranted to guide management decisions.

It is crucial to document all findings and interventions in the patient's medical record and to report any adverse events to the appropriate regulatory authorities as required.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients not to apply the product on irritated, infected, or reddened skin, as well as to avoid use on genital warts and warts located on the face. Patients should also be informed that the product should not be used on moles, birthmarks, or warts that have hair growing from them, and it must not be applied to mucous membranes.

Additionally, healthcare providers should recommend that patients consult with a doctor prior to use if they have diabetes or experience poor blood circulation. This precaution is essential to ensure the safe and effective use of the product.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59° to 86°F (15° to 30°C) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

Patients should consult a healthcare professional prior to use if they have diabetes or poor blood circulation. No further information is available regarding laboratory tests, abuse potential, route, method, and frequency of administration, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Txl Active Wart Remover Pads, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)